DOCSLIB.ORG

Alzheimer's Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alzheimer's Disease VU Research Portal Spot the difference Bossers, C.A.M. 2009 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Bossers, C. A. M. (2009). Spot the difference: microarray analysis of gene expression changes in Alzheimer's and Parkinson's Disease. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 11. Oct. 2021 Spot the difference: microarray analysis of gene expression changes in Alzheimer’s and Parkinson’s Disease The research described in this thesis was conducted at the Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sci- ences, Amsterdam, The Netherlands. The research was financially supported by a collaboration between the Netherlands Institute for Neuroscience and Solvay Phar- maceuticals. Leescommissie: dr. P. Broqua prof.dr. P. Heutink dr. P.A.C. ‘t Hoen prof.dr. H.P.H. Kremer prof.dr. A.B. Smit dr. G.C.M. Zondag Publication of this thesis was financially supported by: Solvay Pharmaceuticals Eurogentec Vrije Universiteit Nederlands Instituut voor Neurowetenschappen ISBN 978-94-90371-05-0 Book and cover design: Koen Bossers Print: Off Page, Amsterdam No part of this publication may be reproduced, stored of transmitted in any way with- out written permission from the author. VRIJE UNIVERSITEIT Spot the difference: microarray analysis of gene expression changes in Alzheimer’s and Parkinson’s Disease ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus prof.dr. L.M. Bouter, in het openbaar te verdedigen ten overstaan van de promotiecommissie van de faculteit der Aard- en Levenswetenschappen op dinsdag 10 november 2009 om 10.45 uur in het auditorium van de universiteit, De Boelelaan 1105 door Conrad Antonius Martinus Bossers geboren te Nijmegen promotoren: prof.dr. J. Verhaagen prof.dr. D.F. Swaab prof.dr. C.G. Kruse Contents Chapter 1 General introduction 7 Bossers K, Verhaagen J, Swaab DF Chapter 2 Scope and outline 29 Chapter 3 Analysis of gene expression in Parkinson’s disease: possible 35 involvement of neurotrophic support and axon guidance in dopaminergic cell death Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, Swaab DF, Verhaagen J; (2009) Brain Pathol. 19, 91-107. Chapter 4 Intensity-based analysis of dual-color gene expression data 75 as an alternative to ratio-based analysis to enhance reproducibility Bossers K, Ylstra B, Brakenhoff RH, Smeets SJ, Verhaagen J, Van de Wiel MA; submitted Chapter 5 Gene expression changes in the human prefrontal cortex 99 during the progression of Alzheimer’s Disease Bossers K, Meerhoff G, Essing A, Van Dongen J, Houba P, Kruse CG, Verhaagen J, Swaab DF; submitted Chapter 6 A meta-analysis of microarray-based gene expression studies 135 in Alzheimer’s disease Bossers K, Heetveld S, Swaab DF, Verhaagen J; manuscript in preparation Chapter 7 Neurosteroid biosynthetic pathways changes in the 153 Alzheimer’s disease prefrontal cortex Luchetti S, Bossers K, Van de Bilt S, Agrapart V, Ramirez Morales R, Vanni Frajese G, Swaab DF; submitted Chapter 8 General discussion 175 Bossers K, Swaab DF, Verhaagen J List of references 207 Nederlandse samenvatting 229 Dankwoord 235 Curriculum vitae 237 chapter 1 General introduction Koen Bossers, Joost Verhaagen, Dick F. Swaab GeNerAl introduction 1. Introduction In a population that is growing older and older, it is difficult to underestimate the impact of age-related neurodegenerative disorders such as Parkinson’s Disease (PD) and Alzheimer’s Disease (AD). In particular, the absence of treatment options to effectively treat, or even slow down the progression of these disorders means that individuals diagnosed with AD or PD face a long and debilitating disease with an inevitably negative outcome. This introduction will first focus on the clinical and neuropathological characteristics of PD and AD. Subsequently, advances in the understanding of putative molecular mechanisms underlying neurodegenerative events, mostly based on studies of rare familial variants of PD and AD, will be dis- cussed. As mentioned, effective treatment regimes remain conspicuously absent, despite enormous research efforts during the last two decades. Therefore, the final part of this introduction will focus on new research strategies that might help to provide insight in the biological mechanisms that contribute to AD- or PD-associ- ated neurodegeneration. 2. Parkinson’s Disease Parkinson’s Disease (PD) is a severe movement disorder which is neuropathological- ly characterized by a dramatic and selective loss of dopaminergic (DAergic) neurons in the substantia nigra (SN). The clinical symptoms usually only arise when ~60% of the SN DAergic neurons is lost, and the levels of DA in the putamen are de- creased by as much as 80%. The disease course is progressive, and the incidence in- creases strongly with age: the overall incidence is 1:5000, which increases to ~1:800 at age 70 (reviewed in Dauer and Przedborski 2003). early in the disease course, PD motor symptoms can be effectively treated with DA replacement therapies. How- ever, this treatment is only symptomatic and does not halt disease progression. The molecular mechanisms underlying PD-associated neurodegeneration remain poorly understood. 2.1 Clinical features of PD Clinically, PD manifests itself as a movement disorder characterized by, amongst others, resting tremors, rigidity, difficulties with voluntary movement and postural instability. The quality of life of a PD patient is most severely affected by the distur- bances in voluntary movement. Patients often have problems initiating movements, and move more slowly (bradykinesia). Other notable movement disturbances in- clude a stooped posture, decreased volume of speaking (hypophonia) and reduced degree of facial expression (hypomimia). Not surprisingly, PD patients develop dif- ficulties in performing simple daily routines such as getting dressed and walking the dog. Furthermore, the combined effects of hypophonia, hypomimia and the fact that PD patients often take longer to reply to questions, can pose a serious hin- 9 chapter 1 drance to the patient’s social life. Also, depression and social withdrawal are often observed in PD patients (reijnders et al. 2008). Apart from motor symptoms, PD patients are at greater risk for developing cog- nitive defects and dementia. It has been reported that around one-third of newly- diagnosed PD patients without dementia are cognitively impaired in areas such as executive function and working memory (Foltynie et al. 2004). This impairment may result from disruption of striatofrontal connections such as the mesocortical DAergic system. Indeed, executive function performance depends on DA levels (lewis et al. 2005; Lange et al. 1995). Furthermore, ~30% of PD patients develop dementia (Aarsland et al. 2005). The strongest neuropathological correlate for this finding is a reduced cholinergic activity in the cortex, secondary to degeneration of the nucleus basalis of Meynert (Bosboom et al. 2004). The presence of lewy Body (lB, discussed below) pathology in limbic and frontal areas might also contribute to symptoms of dementia in PD. However, AD-associated neuropathological altera- tions are frequently co-existent with lB pathology (emre 2003). Thus, the exact neuropathological correlate with dementia in PD remains unclear. 2.2 Neuropathological features of PD The main neuropathological hallmark of PD is the selective loss of DAergic neurons in the SN. This is accompanied by two specific types of intraneuronal proteinacious inclusions: spindle- or threadlike lewy neurites (lN), and globular lewy bodies (lB) near the nucleus. However, the SN is not the only brain area affected in PD. In fact, PD-associated lesions appear in a precisely defined order in different brain areas, and the SN is only affected after the appearance of PD lesions in other brain areas. In 2003, Braak et al published a method for staging the progression of PD (Braak et al. 2003). The first two stages are characterized by lesions in the dorsal IX/X motor nucleus and/or the intermediate reticular zone (stage 1), followed by lesions in the raphe nuclei, gigantocellular reticular nucleus and the coereulus/sub- coereulus complex (stage 2). In stage 3, the SN, in particular the pars compacta, becomes affected. Cortical involvement only occurs in later stages: the first lesions appear in the mesocortex (stage 4), whereas pathology in the neocortex is only ob- served in stages 5 and 6. Although the SN is not the area where PD-associated lesions first appear, it is the most significantly affected area. The overall loss of neuromelanin-positive DAergic neurons in end-stage PD is ~80% (Damier et al. 1999), resulting in a dramatic re- duction of DA output via the nigrostriatal pathway to the target areas of the SN: the caudate nucleus and putamen. especially the DAergic innervation of the caudate nucleus is severely reduced. The motor disturbances observed in PD arise from the loss of DA input into the striatum. 10 GeNerAl introduction 2.3 Treatment strategies for PD As the main symptoms of PD arise from a reduced DA level in the striatum, it is not surprising that the main treatment strategy for PD is the replenishment of stri- atal DA levels (DA replacement therapy).
Load more

Recommended publications
  • Analysis of BMP4 and BMP7 Signaling in Breast Cancer Cells Unveils Time
    Rodriguez-Martinez et al. BMC Medical Genomics 2011, 4:80 http://www.biomedcentral.com/1755-8794/4/80 RESEARCHARTICLE Open Access Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes Alejandra Rodriguez-Martinez1†, Emma-Leena Alarmo1†, Lilli Saarinen2, Johanna Ketolainen1, Kari Nousiainen2, Sampsa Hautaniemi2 and Anne Kallioniemi1* Abstract Background: Bone morphogenetic proteins (BMPs) are members of the TGF-beta superfamily of growth factors. They are known for their roles in regulation of osteogenesis and developmental processes and, in recent years, evidence has accumulated of their crucial functions in tumor biology. BMP4 and BMP7, in particular, have been implicated in breast cancer. However, little is known about BMP target genes in the context of tumor. We explored the effects of BMP4 and BMP7 treatment on global gene transcription in seven breast cancer cell lines during a 6- point time series, using a whole-genome oligo microarray. Data analysis included hierarchical clustering of differentially expressed genes, gene ontology enrichment analyses and model based clustering of temporal data. Results: Both ligands had a strong effect on gene expression, although the response to BMP4 treatment was more pronounced. The cellular functions most strongly affected by BMP signaling were regulation of transcription and development. The observed transcriptional response, as well as its functional outcome, followed a temporal sequence, with regulation of gene expression and signal transduction leading to changes in metabolism and cell proliferation. Hierarchical clustering revealed distinct differences in the response of individual cell lines to BMPs, but also highlighted a synexpression group of genes for both ligands.
    [Show full text]
  • Epidermal Growth Factor Receptor (EGFR) Mutation Analysis, Gene
    Peraldo-Neia et al. BMC Cancer 2011, 11:31 http://www.biomedcentral.com/1471-2407/11/31 RESEARCHARTICLE Open Access Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer Caterina Peraldo-Neia1,2*, Giorgia Migliardi1, Maurizia Mello-Grand2, Filippo Montemurro3, Raffaella Segir2, Ymera Pignochino1, Giuliana Cavalloni1, Bruno Torchio4, Luciano Mosso4, Giovanna Chiorino2, Massimo Aglietta1,3 Abstract Background: Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to the tyrosine kinase inhibitors (TKi), gefitinib and erlotinib. We analysed EGFR expression, EGFR mutation status and gene expression profiles of prostate cancer (PC) to supply a rationale for EGFR targeted therapies in this disease. Methods: Mutational analysis of EGFR TK domain (exons from 18 to 21) and immunohistochemistry for EGFR were performed on tumour tissues derived from radical prostatectomy from 100 PC patients. Gene expression profiling using oligo-microarrays was also carried out in 51 of the PC samples. Results: EGFR protein overexpression (EGFRhigh) was found in 36% of the tumour samples, and mutations were found in 13% of samples. Patients with EGFRhigh tumours experienced a significantly increased risk of biochemical relapse (hazard ratio-HR 2.52, p=0.02) compared with patients with tumours expressing low levels of EGFR (EGFRlow). Microarray analysis did not reveal any differences in gene expression between EGFRhigh and EGFRlow tumours. Conversely, in EGFRhigh tumours, we were able to identify a 79 gene signature distinguishing mutated from non-mutated tumours. Additionally, 29 genes were found to be differentially expressed between mutated/ EGFRhigh (n=3) and mutated/EGFRlow tumours (n=5).
    [Show full text]
  • Macropinocytosis Requires Gal-3 in a Subset of Patient-Derived Glioblastoma Stem Cells
    ARTICLE https://doi.org/10.1038/s42003-021-02258-z OPEN Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells Laetitia Seguin1,8, Soline Odouard2,8, Francesca Corlazzoli 2,8, Sarah Al Haddad2, Laurine Moindrot2, Marta Calvo Tardón3, Mayra Yebra4, Alexey Koval5, Eliana Marinari2, Viviane Bes3, Alexandre Guérin 6, Mathilde Allard2, Sten Ilmjärv6, Vladimir L. Katanaev 5, Paul R. Walker3, Karl-Heinz Krause6, Valérie Dutoit2, ✉ Jann N. Sarkaria 7, Pierre-Yves Dietrich2 & Érika Cosset 2 Recently, we involved the carbohydrate-binding protein Galectin-3 (Gal-3) as a druggable target for KRAS-mutant-addicted lung and pancreatic cancers. Here, using glioblastoma patient-derived stem cells (GSCs), we identify and characterize a subset of Gal-3high glio- 1234567890():,; blastoma (GBM) tumors mainly within the mesenchymal subtype that are addicted to Gal-3- mediated macropinocytosis. Using both genetic and pharmacologic inhibition of Gal-3, we showed a significant decrease of GSC macropinocytosis activity, cell survival and invasion, in vitro and in vivo. Mechanistically, we demonstrate that Gal-3 binds to RAB10, a member of the RAS superfamily of small GTPases, and β1 integrin, which are both required for macro- pinocytosis activity and cell survival. Finally, by defining a Gal-3/macropinocytosis molecular signature, we could predict sensitivity to this dependency pathway and provide proof-of- principle for innovative therapeutic strategies to exploit this Achilles’ heel for a significant and unique subset of GBM patients. 1 University Côte d’Azur, CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging (IRCAN), Nice, France. 2 Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
    [Show full text]
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • Supplemental Figure and Table Legends
    Supplemental figure and table legends Supplementary Figure 1: KIAA1841 is well conserved among vertebrates. NCBI HomoloGene pairwise alignment scores of human KIAA1841 sequence compared to other vertebrate orthologs. Supplementary Figure 2: µ-germline transcripts (GLT) and AID mRNA expression are not affected by overexpression of KIAA1841. Splenic B cells were isolated from wild-type mice, and transduced with retroviral vector control (pMIG) or a vector expressing KIAA1841. Levels of µ-GLT and AID mRNA were determined at 72h post-infection by RT-qPCR, and normalized to -actin mRNA and the pMIG control. The mean of three independent experiments +/- SD is shown. NS, p = not significant, p 0.05, two-tailed paired student’s t-test. Supplementary Figure 3: Overexpression of untagged and Xpress-tagged KIAA1841 does not affect cell proliferation. Splenic B cells were isolated from wild-type mice, stimulated with LPS+IL4, and transduced with retroviral vector control (pMIG) or a vector expressing KIAA1841 or Xpress (Xp)-tagged KIAA1841. Cells are labeled with seminaphthorhodafluor (SNARF) cell tracking dye and SNARF intensity was measured at 0h, 24h, and 48h after retroviral infection. Histograms of transduced cells (GFP+) for pMIG control, KIAA1841 and Xp-KIAA1841 were superimposed at each time point. Three independent retroviral infection experiments are shown. Supplementary Figure 4: Sequence alignment of the putative SANT domain of KIAA1841 with the SANT domain of SWI3. Alignment was performed using ClustalOmega; *, conserved residue, :, strongly similar residues, ., weakly similar residues. Numbers indicate amino acid residues in each sequence. Helix 3, which has been reported to be important for the chromatin remodeling function of SWI3 (Boyer et.
    [Show full text]
  • Biallelic Mutation of FBXL7 Suggests a Novel Form of Hennekam Syndrome
    Bi Weimin (Orcid ID: 0000-0002-1330-7031) RODAN Lance (Orcid ID: 0000-0002-2392-6688) Boone Philip (Orcid ID: 0000-0001-9528-252X) RODAN Lance (Orcid ID: 0000-0002-2392-6688) 1 Biallelic mutation of FBXL7 suggests a novel form of Hennekam syndrome Philip M. Boone MD PhD,1,2,3,4,5 Scott Paterson BSc,6 Kiana Mohajeri BS,3,4,5,7 Wenmiao Zhu MS,8 Casie A. Genetti MS,9 Derek J. C. Tai PhD,3,4,5 Neeharika Nori BS,9 Pankaj B. Agrawal MD,2,9,10 Carlos A. Bacino MD,8 Weimin Bi, PhD,8 Michael E. Talkowski PhD,3,4,5 Benjamin M. Hogan PhD,6 Lance H. Rodan, MD2,11* 1) Harvard Genetics Training Program, Boston, MA, USA; 2) Division of Genetics and Genomics, Boston Children’s Hospital, Boston; 3) Center for Genomic Medicine, Massachusetts General Hospital, Boston; 4) Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; 5) Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA; 6) Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia; 7) PhD Program in Biological and Biomedical Sciences, Harvard Medical School, Boston; 8) Baylor Genetics, Houston, TX, USA; 9) The Manton Center for Orphan Disease Research, Boston Children’s Hospital; 10) Division of Newborn Medicine, Boston Children’s Hospital; 11) Department of Neurology, Boston Children’s Hospital This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Persistent Transcription-Blocking DNA Lesions Trigger Somatic Growth Attenuation Associated with Longevity
    ARTICLES Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity George A. Garinis1,2, Lieneke M. Uittenboogaard1, Heike Stachelscheid3,4, Maria Fousteri5, Wilfred van Ijcken6, Timo M. Breit7, Harry van Steeg8, Leon H. F. Mullenders5, Gijsbertus T. J. van der Horst1, Jens C. Brüning4,9, Carien M. Niessen3,9,10, Jan H. J. Hoeijmakers1 and Björn Schumacher1,9,11 The accumulation of stochastic DNA damage throughout an organism’s lifespan is thought to contribute to ageing. Conversely, ageing seems to be phenotypically reproducible and regulated through genetic pathways such as the insulin-like growth factor-1 (IGF-1) and growth hormone (GH) receptors, which are central mediators of the somatic growth axis. Here we report that persistent DNA damage in primary cells from mice elicits changes in global gene expression similar to those occurring in various organs of naturally aged animals. We show that, as in ageing animals, the expression of IGF-1 receptor and GH receptor is attenuated, resulting in cellular resistance to IGF-1. This cell-autonomous attenuation is specifically induced by persistent lesions leading to stalling of RNA polymerase II in proliferating, quiescent and terminally differentiated cells; it is exacerbated and prolonged in cells from progeroid mice and confers resistance to oxidative stress. Our findings suggest that the accumulation of DNA damage in transcribed genes in most if not all tissues contributes to the ageing-associated shift from growth to somatic maintenance that triggers stress resistance and is thought to promote longevity. Ageing represents the progressive functional decline that is exempted levels as a result of pituitary dysfunction (Snell and Ames mice) — have an from evolutionary selection because it largely occurs after reproduc- extended lifespan17–20.
    [Show full text]
  • Anti-Aurora a Antibody [1A11] (ARG11120)
    Product datasheet [email protected] ARG11120 Package: 100 μl anti-Aurora A antibody [1A11] Store at: -20°C Summary Product Description Mouse Monoclonal antibody [1A11] recognizes Aurora A Tested Reactivity Hu, Ms Species Does Not React With Dog, Hrs Tested Application ICC/IF, IHC-Fr, WB Specificity This antibody was made against recombinant human aurora A, and was shown to be non-reactive with aurora B or C. Host Mouse Clonality Monoclonal Clone 1A11 Isotype IgG1 Target Name Aurora A Antigen Species Human Immunogen Recombinant full-length Human Aurora A. Conjugation Un-conjugated Alternate Names ARK-1; AIK; BTAK; Serine/threonine-protein kinase 6; Breast tumor-amplified kinase; Serine/threonine- protein kinase aurora-A; STK15; Serine/threonine-protein kinase 15; AURORA2; Aurora-related kinase 1; hARK1; AURA; STK6; STK7; Aurora kinase A; EC 2.7.11.1; Aurora/IPL1-related kinase 1; Aurora 2; ARK1; PPP1R47 Application Instructions Application table Application Dilution ICC/IF 1:100 - 1:500 IHC-Fr 1:100 - 1:500 WB 1:100 - 1:500 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 46 kDa Observed Size ~ 46 kDa Properties Form Liquid Buffer Concentrated hybridoma cell culture media and 5 mM Sodium azide. www.arigobio.com 1/3 Preservative 5 mM Sodium azide Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles.
    [Show full text]